tradingkey.logo

Esperion Therapeutics Inc <ESPR.OQ> expected to post a loss of 15 cents a share - Earnings Preview

ReutersFeb 28, 2025 2:17 PM
  • Esperion Therapeutics Inc ESPR.OQ ESPR.O is expected to show a rise in quarterly revenue when it reports results on March 4 for the period ending December 31 2024

  • The Ann Arbor Michigan-based company is expected to report a 91.0% increase in revenue to $61.585 million from $32.25 million a year ago, according to the mean estimate from 9 analysts, based on LSEG data.

  • ​LSEG's mean analyst estimate for Esperion Therapeutics Inc is for a loss of 15 cents per share.

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy," 2 "hold" and 1 "sell" or "strong sell."

  • The mean earnings estimate of analysts was unchanged in the last three months. ​

  • Wall Street's median 12-month price target for Esperion Therapeutics Inc is $5.50​, above​ its last closing price of $1.66. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING

STARMINESMARTESTIMATE®

LSEG IBES ESTIMATE

ACTUAL

BEAT, MET, MISSED

SURPRISE %

Sep. 30 2024

-0.18

-0.18

-0.15

Beat

14.6

Jun. 30 2024

-0.17

-0.18

-0.33

Missed

-79.2

Mar. 31 2024

0.08

0.05

0.34

Beat

627.3​

Dec. 31 2023

-0.41

-0.48

-0.50

Missed

-3.6

​​Sep. 30 2023

-0.43

-0.43

-0.37

Beat

14.4

Jun. 30 2023

-0.62

-0.61

-0.46

Beat

24.8​

Mar. 31 2023

-0.64

-0.65

-0.79

Missed

-21.1

Dec. 31 2022

-0.82

-0.84

-0.76

Beat

9.6

This summary was machine generated February 28 at 14:17 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI